The Phase II trial will study the efficacy of medical cannabis on breathlessness, and exercise tolerance in symptomatic patients with advanced COPD. “Tilray is proud to support this important research,” said Dr. Catherine Jacobson, Director of Clinical Research at Tilray.
The Tilray Medical Advisory Board is an internationally recognized group of researchers and physicians who are committed to facilitating groundbreaking advancements in the emerging field of cannabinoid science.
The Tilray team gathered at Tilray's medical cannabis research and production facility in Nanaimo, British Columbia to reflect on a spectacular year of progress for the company, the industry and — most importantly — for patients in Canada and around the world.
Proceeds from ticket sales were donated Marley Natural's Rise Up initiative to benefit the Minority Cannabis Business Association, an organization that aims to increase diversity in the cannabis industry.